Literature DB >> 20927755

Antimicrobial agents for treating uncomplicated urinary tract infection in women.

Anca Zalmanovici Trestioreanu1, Hefziba Green, Mical Paul, John Yaphe, Leonard Leibovici.   

Abstract

BACKGROUND: Acute uncomplicated lower urinary tract infection (UTI) is one of the most common problems for which young women seek medical attention.
OBJECTIVES: To compare the efficacy, resistance development and safety of different antimicrobial treatments for acute uncomplicated lower UTI. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Renal Group's Specialised Register, MEDLINE, EMBASE and bibliographies of included studies. SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing different classes of antimicrobials for acute uncomplicated UTI in women were included. The outcomes of interest were symptomatic and bacteriological cure at short and long-term follow-up, resistance development, number of days to symptom resolution, days of work loss, adverse events and complications. DATA COLLECTION AND ANALYSIS: Two authors independently extracted the data and assessed study quality. Statistical analyses were performed using the random effects model and the results expressed as risk ratios (RR) with 95% confidence intervals (CI). MAIN
RESULTS: Trimethoprim-sulfamethoxazole (TMP-SMX) was as effective as fluoroquinolones in achieving short-term (RR 1.00, 95% CI 0.97 to 1.03) and long-term (RR 0.99, 95% CI 0.94 to 1.05) symptomatic cure. Beta-lactam drugs were as effective as TMP-SMX for short-term (RR 0.95' 95% CI 0.81 to 1.12) and long-term (RR 1.06' 95% CI 0.93 to 1.21) symptomatic cure. Short-term cure for nitrofurantoin was similar to that of TMP-SMX (RR 0.99' 95% CI 0.95 to 1.04) as was long-term symptomatic cure (RR 1.01' 95% CI 0.94 to 1.09).Fluoroquinolones were more effective than beta-lactams (RR 1.22, 95% CI 1.13 to 1.31) for short-term bacteriological cure. Rashes were more frequent in patients treated with TMP-SMX than with nitrofurantoin or fluoroquinolones and in patients treated with beta-lactam drugs compared to fluoroquinolones. Minimal data were available on the emergence of resistant strains during or after antimicrobial treatment. AUTHORS'
CONCLUSIONS: No differences were observed between the classes of antimicrobials included in this review for the symptomatic cure of acute uncomplicated UTI. Fluoroquinolones proved more effective than beta-lactams for the short-term bacteriological outcome, probably with little clinical significance. Individualised treatment should take into consideration the predictable susceptibility of urinary pathogens in local areas, possible adverse events and resistance development, and patient preference.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20927755     DOI: 10.1002/14651858.CD007182.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  23 in total

1.  Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial.

Authors:  Ann E Stapleton; James Dziura; Thomas M Hooton; Marsha E Cox; Yuliya Yarova-Yarovaya; Shu Chen; Kalpana Gupta
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 2.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

3.  Uncomplicated Bacterial Community-Acquired Urinary Tract Infection in Adults.

Authors:  Jennifer Kranz; Stefanie Schmidt; Cordula Lebert; Laila Schneidewind; Guido Schmiemann; Florian Wagenlehner
Journal:  Dtsch Arztebl Int       Date:  2017-12-15       Impact factor: 5.594

4.  Antibiotic treatment of women with uncomplicated cystitis before and after allowing pharmacist-supply of trimethoprim.

Authors:  Natalie J Gauld; Irene S L Zeng; Rosemary B Ikram; Mark G Thomas; Stephen A Buetow
Journal:  Int J Clin Pharm       Date:  2016-12-23

5.  Uncomplicated urinary tract infections.

Authors:  Florian M E Wagenlehner; Udo Hoyme; Martin Kaase; Reinhard Fünfstück; Kurt G Naber; Guido Schmiemann
Journal:  Dtsch Arztebl Int       Date:  2011-06-17       Impact factor: 5.594

6.  Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care.

Authors:  Arjen F J Geerts; Willemijn L Eppenga; Rob Heerdink; Hieronymus J Derijks; Michel J P Wensing; Toine C G Egberts; Peter A G M De Smet
Journal:  Eur J Clin Pharmacol       Date:  2013-05-10       Impact factor: 2.953

7.  Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Authors:  Angela Huttner; Anna Kowalczyk; Adi Turjeman; Tanya Babich; Caroline Brossier; Noa Eliakim-Raz; Katarzyna Kosiek; Begoña Martinez de Tejada; Xavier Roux; Shachaf Shiber; Ursula Theuretzbacher; Elodie von Dach; Dafna Yahav; Leonard Leibovici; Maciek Godycki-Cwirko; Johan W Mouton; Stephan Harbarth
Journal:  JAMA       Date:  2018-05-01       Impact factor: 56.272

8.  Evaluation of the efficacy and safety of high dose short duration enrofloxacin treatment regimen for uncomplicated urinary tract infections in dogs.

Authors:  J L Westropp; J E Sykes; S Irom; J B Daniels; A Smith; D Keil; T Settje; Y Wang; D J Chew
Journal:  J Vet Intern Med       Date:  2012-04-04       Impact factor: 3.333

9.  Antimicrobial management and appropriateness of treatment of urinary tract infection in general practice in Ireland.

Authors:  Akke Vellinga; Martin Cormican; Belinda Hanahoe; Kathleen Bennett; Andrew W Murphy
Journal:  BMC Fam Pract       Date:  2011-10-03       Impact factor: 2.497

10.  Evaluation of the prevalence of urinary tract infection in rural Panamanian women.

Authors:  Suzanne L August; Michael J De Rosa
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.